Mgmt lunch takeaways: CTCL pivotal in sight, BI-1206 triplet poised to improve
Yesterday, we attended a lunch organised by BioInvent's management, where the team provided updated colour on lead programs BI-1808 in CTCL and BI-1206 in NHL. An important strategic focus for the company is the advancement of BI-1808 in CTCL, where early signs of clinical activity in both Sézary S
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.